Paul Stoffels

Dr. Paul Stoffels joined Galapagos as CEO* in April 2022. Prior to that, he was Vice Chairman of the Executive Committee and CSO of Johnson & Johnson, where he set the company wide innovation agenda and led the pharmaceutical R&D pipeline as well as the external initiatives. Before that, he was worldwide Chairman Pharmaceuticals of Johnson & Johnson, which, under his leadership, significantly rejuvenated its product pipeline and adopted a transformational R&D operating model, resulting in the launch of 25 innovative medicines across the globe. Dr Stoffels joined Johnson & Johnson in 2002, with the acquisition of Virco and Tibotec, where he was CEO and Chairman respectively, and where he led the development of several breakthrough products for the treatment of HIV. Dr Stoffels is currently a member of the Supervisory Board of Philips Healthcare in the Netherlands.
*Stoffels IMC BV, permanently represented by Dr. Paul Stoffels